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Abstract The present study investigated the impact of
comorbidity over and above the impact of symptom
severity on treatment outcome of Cognitive Behavioral
Therapy for children with anxiety disorders. Children (aged
8–12, n=124) diagnosed with an anxiety disorder were
treated with a short-term CBT protocol. Severity was
assessed with a composite measure of parent-reported
behavior problems. Two approaches to comorbidity were
examined; “total comorbidity” which differentiated anxiety
disordered children with (n=69) or without (n=55) a co-
occurring disorder and “non-anxiety comorbidity’ which
differentiated anxious children with (n=22) or without a
non-anxiety comorbid disorder (n=102). Treatment out-
come was assessed in terms of Recovery, represented by
post-treatment diagnostic status, and Reliable Change, a
score reflecting changes in pre- to post-treatment symptom
levels. Severity contributed to the prediction of (no)
Recovery and (more) Reliable Change in parent-reported
internalizing and externalizing symptoms and self-reported
depressive symptoms. Total and non-anxiety comorbidity
added to the prediction of diagnostic recovery. Non-anxiety
comorbidity added to the prediction of Reliable Change in
parent reported measures by acting as a suppressor variable.
Non-anxiety comorbidity operated as a strong predictor that
explained all of the variance associated with severity for
self-reported depressive symptoms. The results support the
need for further research on mechanisms by which
treatment gains in children with higher symptom severity
and non-anxiety comorbidity can be achieved.
Keywords Childhoodanxietydisorders.Cognitivebehavior
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Severity and Comorbidity as Predictors of CBT
Outcome for Childhood Anxiety Disorders
A recent review supports the efficacy of Cognitive Behavioral
Therapy (CBT) for Childhood Anxiety Disorders (CAD) and
accords CBT the status of an empirically supported treatment
(Cartwright-Hatton et al. 2004). However, a significant
number of children (20 to 60 percent) that participate in
research trials for CAD, do not show an adequate treatment
response (Compton et al. 2002). Predictors of treatment
response are of clinical and theoretical value (Rapee 2000)
for identifying the mechanisms that facilitate or hinder
treatment recovery. Two possible child predictors for
treatment outcome for CAD are initial symptom severity
and comorbidity.
In previous studies symptom severity has been associated
with less favorable treatment outcomes in school-refusing
youth, in which baseline school attendance represented
severity (Layne et al. 2003). In another study the long-
term outcome of child CBT for anxiety disorders was also
J. M. Liber: B. M. van Widenfelt: A. J. M. van der Leeden:
A. W. Goedhart: P. D. A. Treffers
Department of Child and Adolescent Psychiatry,
Curium/ Leiden University Medical Center,
Leiden, the Netherlands
E. M. W. J. Utens
Department of Child and Adolescent Psychiatry,
Erasmus Medical Center Rotterdam/ Sophia Children’s Hospital,
Rotterdam, the Netherlands
J. M. Liber (*)
Curium,
Endegeesterstraatweg 27,
2342 AK Oegstgeest, the Netherlands
e-mail: J.M.Liber@uva.nl
J Abnorm Child Psychol (2010) 38:683–694
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the pretreatment scores on child-reported anxiety (Manassis
et al. 2004). In a study of exposure-based CBT for phobic
and anxiety disorders in youth mixed findings were
reported: child-reported anxiety and depression severity
predicted less favorable treatment outcome, but parent
reported severity measures did not show any predictive
value (Berman et al. 2000). In contrast, in a study of CBT
for children with anxiety disorders parent reported child
withdrawal symptoms predicted poor outcome while no
associations were found with child-reported (e.g. anxiety
and depression) severity measures (Southam-Gerow et al.
2001). Together, these results suggest that initial symptom
severity is a good predictor of treatment outcome of CBT
for CAD. However, we found no studies on the predictive
value of measures of overall severity operationalized as
total symptom count or total problem scores.
To date, most studies investigating the treatment outcome
of CBT for CAD have not found an impact of diagnostic
comorbidity on treatment recovery (Flannery-Schroeder et al.
2004; Kendall et al. 2001; Rapee 2003). One study found an
association between comorbid depression and poor treatment
response (Berman et al. 2000). Rapee (2003)f o u n dn o
differences in treatment response at post-treatment, and
negligible differences at 6 months follow-up between three
groups of anxious children and adolescents; an anxiety
disorder and no comorbid disorder group, a more than one
anxiety disorder group and an anxiety disorder and comorbid
disorder other than anxiety (mood disorder or externalizing
disorder) group. At 6 months follow-up there was a slight
increase of father-reported internalizing symptoms and
mother-reported externalizing symptoms in the children with
other comorbidity, whereas children with one or more
anxiety disorders and no non-anxiety comorbid disorders
still showed a decline in internalizing symptoms.
While studies suggest that CBT is equally effective
for anxiety disordered children with or without comor-
bid disorders, it is premature to assume that a standard
brief CBT program used in research trials will work as
well for complex cases such as those that present
themselves in non-research settings (Southam-Gerow et
al. 2008). In addition, comorbidity has repeatedly been
suggested to negatively impact treatment processes (e.g.,
Kennard et al. 2005). For clinical practice it is important
to assess whether comorbidity is a clinically significant
co-occurrence (Starcevic 2005) with possible unique
effects on treatment outcome. To our knowledge research
examining the unique impact of comorbidity on treatment
outcome for childhood anxiety disorders above and
beyond the impact of severity is scarce.
In the present study we use a measure of overall severity
(i.e., the Total Problem score of the CBCL that has been
validated as a measure indicating caseness, see Kasius et al.
(1997)). We further study the impact of both continuous
and categorical outcome measures to examine the unique
impact of comorbidity. Comorbidity and overall severity,
though closely related, are for the purposes of this study
viewed as distinct concepts, with comorbidity referring to
the co-occurrence of two or more psychiatric disorders, and
overall severity referring to the number of symptoms
regardless of diagnostic status.
Two patterns of co-occurrence of psychiatric diagnoses
are examined: total comorbidity, defined as any pattern of
co-occurrence, and non-anxiety comorbidity, defined as the
co-occurrence of one or more anxiety and one or more non-
anxiety disorders. Total comorbidity reflects the broad
definition of comorbidity as the co-occurrence of two or
more psychiatric diagnoses (Starcevic 2005). Non-anxiety
comorbidity originates from the proposal of Angold et al.
(1999) to make a distinction between two types of
comorbidity that tend to have different implications:
homotypic comorbidity (i.e., comorbidity between disor-
ders within a diagnostic grouping, such as anxiety
disorders) and heterotypic comorbidity (i.e., comorbidity
between disorders from different diagnostic groupings). As
the high level of comorbidity of different anxiety disorders
may reflect the possible artificiality of the subdivision of
anxiety disorders into many different syndromes (Caron
and Rutter 1991), we decided to focus on non-anxiety
comorbidity, i.e. the heterotypic comorbidity of one or more
anxiety disorders and one or more non-anxiety disorders.
Total comorbidity in contrast reflects the number of
disorders regardless the nature of the comorbid disorder(s).
It is important when studying predictors of treatment
outcome to effectively evaluate the nature and degree of
change that has occurred as a result of therapy. Estimation
of pre- to post-treatment change is often inferred by
calculating differences between pre and post-treatment
scores on primary outcome measures, e.g., by using a
repeated measures design including time. A serious
drawback of using pre-post difference scores is that
measurement-error (error-based regression to the mean)
is not taken into account (Hageman and Arrindell
1999). Hageman and Arrindell therefore proposed proce-
dures to establish Reliable Change and clinically signifi-
cant change. Furthermore, recovery usually reflects the
clinical post-treatment symptom-status given the pretreat-
ment symptom status; e.g., a disorder that was present
before treatment, is present (i.e., no recovery) or absent
(recovery) at post treatment. If continuous outcome
measures are used to estimate recovery, then both pre-
post change and a cut-off score (dividing ‘normal’ from
‘abnormal’ scores) for post-treatment should be used (e.g.
recovery is defined as: a significant pre-post change and a
post-treatment score in the normal range). In recent years,
it has become more common for treatment outcome
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ingful change (i.e., Shortt et al. 2001; Silverman et al.
1999). Even these studies did not take measurement-error
into account when using continuous measures in comput-
ing treatment recovery.
The purpose of the present study was to investigate the
unique impact of pretreatment comorbidity on treatment
outcome for childhood anxiety disorders above and beyond
the impact of severity. The study focuses on the impact of
total and non-anxious comorbidity and overall severity on
outcome by addressing the following questions: (1) Does
total and/or non-anxious comorbidity predict recovery
above and beyond overall severity? (2) Does total and/or
non-anxious comorbidity predict Reliable Change in self-
reported anxiety and parent-reported internalizing symp-
toms above and beyond overall severity? (3) Does total
and/or non-anxious comorbidity predict Reliable Change in
non-anxiety symptoms (self-reported depressive symptoms




The present study is part of a larger treatment outcome study
(see Liber et al. 2008a). Eligible for participation were
children aged 8–12 years referred between September 2002
and December 2005 to the anxiety and depression outpatient
clinic at the Child and Adolescent Psychiatry Department,
Leiden University Medical Center and Erasmus Medical
Center, Sophia Children’s Hospital in Rotterdam, in the
Netherlands. Children diagnosed with a primary disorder of
Separation Anxiety Disorder (SAD), Generalized Anxiety
Disorder (GAD), Social Phobia (SOP) or Specific Phobia
(SP) were eligible for participation. Children were excluded
if they had an IQ below 85 or Pervasive Developmental
Disorder. Children with primary Obsessive Compulsive
Disorder and Posttraumatic Stress Disorder were also
excluded. The reason for exclusion was that in previous
research trials OCD and PTSD were not treated with the
same CBT treatment protocol as other anxiety disorders, but
rather CBT protocols specific for OCD or PTSD. Further,
given that Panic Disorder is uncommon in childhood, it was
also not included in the present study. As part of the routine
procedure of both settings, all children and their parents were
interviewed with the Anxiety Disorders Interview Schedule
(ADIS-C/P; Silverman and Albano 1996).
A total of 142 children principally diagnosed with an
Anxiety Disorder and their parents were asked to participate
in the present study. Of these 142 children and their
families, 133 subjects gave informed consent to participate.
Children who received medication for ADHD (n=5) were
not excluded from the study. Dosage of medication was
kept constant during the study as a constant dosage of
medication for ADHD was considered unlikely to confound
treatment effects. Effects of the medication for ADHD on
anxiety were expected to be stabilized by giving children a
constant dosage. We did not exclude these children in order
to facilitate generalization to normal care. Given that there
were only five children on medication the power was not
sufficient to investigate if medication interacted with
treatment.
Participants were randomly assigned in sequences of 6 to
either group or individual treatment. Sixty-two children (36
boys and 26 girls) participated in the group treatment, and
71 children (38 boys and 33 girls) were individually treated.
The primary diagnoses of the children were SAD (n=53),
GAD (n=39), SOP (n=22) or SP (n=19). The social
economic status (SES) was low for 19 children, medium for
61 children and high for 53 children (Central Bureau of
Statistics Netherlands 2001). Sixteen children had a non-
Dutch ethnic background: Turkish (n=2), Moroccan (n=3),
Surinamese (n=5) and other (n=6).
Nine children dropped out of treatment, which resulted
in a sample of 124 treatment completers. One hundred and
twenty-three mothers and 108 fathers of children who
completed the treatment also participated (for a description
of the parents, see Liber et al. 2008b). Children who
completed treatment or dropped out of treatment did not
differ in the number of pretreatment disorders (t(131)=0.57,
p = ns).
Two types of comorbidity were defined, in line with one
of the approaches to comorbidity described in the intro-
duction. As defined by Starcevic (2005), a dichotomy of
anxious children with no comorbid disorders (n=55) and
anxious children with one or more comorbid disorders (n=
69; total comorbidity) was created. According to the
approach by Caron and Rutter (1991) a dichotomy of
children with one or more anxiety disorders (n=102) and a
group of children with one or more anxiety disorder(s) and
a non-anxiety comorbid disorder (n=22) was created. There
were no significant differences between these groups with
regard to SES, age, gender or primary diagnosis. All results
are based on the sample of children who completed the
treatment unless otherwise specified. Diagnostic informa-
tion and demographic data for the children who completed
treatment are presented in Table 1.
Procedure
Children and parents were interviewed with the ADIS-C/P
(Silverman and Albano 1996) and further assessed with the
routine assessment procedure to confirm clinical diagnosis
of the child. The routine procedure at both sites included at
J Abnorm Child Psychol (2010) 38:683–694 685least one psychiatric consult, intelligence testing, and
assessment of school and family functioning. Symptoms
of anxiety and depression were assessed with the Multi-
dimensional Anxiety Scale for Children (MASC; March
1997) and the Children’s Depression Inventory (CDI;
Kovacs 1992). Clinical case conferences were held to
exclude possible diagnoses not covered in the ADIS-C/P
(i.e., Pervasive Developmental Disorder).
After the initial routine assessment verbal and written
consent were obtained from the parents as well as
children above age 11. Children were then randomly
assigned to individual or group CBT (see Liber et al.
2008a). Prior to starting treatment parents and children
were asked to complete additional questionnaires (see
Measures). All children participating received a manual-
based 10 session weekly cognitive behavioral treatment
and their parents received 4 sessions of cognitive
behavioral parent training (FRIENDS; Barrett and Turner
2000). One week post-treatment children and parents were
again interviewed with the ADIS-C/P and post-treatment
measures were administered to both children and parents.
The present study is part of a larger study on a stepped
care model investigating the effect of an additional
treatment protocol for nonresponders to the initial CBT
program used in the present study. Follow-up data could
be affected by the additional treatment and are therefore
not included in the present study.
Measures
Diagnostic Interview
The ADIS-C/P is a semi-structured interview schedule and
was administered to both parents and children pre- and
post-treatment to obtain clinical information and derive
DSM-IV diagnoses (American Psychiatric Association
2000). The ADIS-C/P is a reliable instrument organized
according to DSM-IV criteria and yields kappa coefficients
for SAD, SOP, SP and GAD ranging from 0.62 to 0.92 for
both the child and the parent interview (Silverman et al.
2001). The ADIS-C/P has strong evidence for providing
reliable and valid diagnoses and sensitivity to clinical
change in treatment outcome research (Silverman and
Ollendick 2005). A Dutch translation of the ADIS-C/P
Variable Total Comorbidity Non-anxiety comorbidity
Comorbid Groups Anx (n=55) ComTot (n=69) Anx-s (n=102) Anx-Other (n=22)
Gender
Male 26 42 56 12
Female 29 27 46 10
Age
Mean (years) 10.06 10.07 10.02 10.30
SD 1.24 1.32 1.28 1.34
SES
Low 8 11 15 4
Middle 21 36 46 11
High 26 22 41 7
Primary Diagnosis
SAD 21 29 39 11
GAD 17 19 30 6
SP 8 11 16 2
SOP 9 10 17 3
Comorbid Diagnosis
SAD – 85 3
GAD – 24 17 7
SP – 28 23 5
SOP – 94 5
Agoraphobia – 22 0
ADHD – 12 – 12
ODD – 6 – 6
Depression – 2 – 2
Dysthymia – 6 – 6
Table 1 Demographic Data on
Diagnostic Groups
Anx single anxiety disorder,
ComTot more than one disorder,
Anx-s one or more anxiety dis-
orders, Anx-Other one or more
anxiety disorders and a co-
occurring non-anxiety disorder.
All group differences were non-
significant at an alpha level of
0.05 (χ² and t-tests). SAD Sepa-
ration Anxiety Disorder, GAD
Generalized Anxiety Disorder,
SP Specific Phobia, SOP Social
Phobia, ADHD Attention Deficit
Hyperactivity Disorder, ODD
Oppositional Defiant Disorder.
686 J Abnorm Child Psychol (2010) 38:683–694was made in close consultation with the original authors
and used in the present study (Siebelink and Treffers 2001).
Guidelines for adequate translation and cross-cultural
adaptation were followed as described in Van Widenfelt et
al. 2005.
Experienced clinicians or master level students adminis-
tered the ADIS-C/P pretreatment. Clinicians of both
institutions met several times to ensure that the procedures
and decision-making were alike. Master level students were
trained by observing live and videotaped interviews and
completed an exam to prove adequate administration of the
interview. The training protocol and examination criteria
can be obtained from the first author upon request.
Supervision was provided and the reports were reviewed
and discussed to ensure that administration, scoring and
reporting would not drift.
Self-report Measures
Information on self-reported child anxiety, anxiety related
and depressive symptoms were obtained by administering
the Dutch versions of the MASC and CDI. The MASC is a
39 item general measure of anxiety translated into Dutch by
Utens and Ferdinand (2000). The internal reliability of the
total score (Cronbach’s alpha of 0.87 for boys and 0.88 for
girls) and the test-retest reliability (3 months) are excellent
(intra class correlation coefficient of 0.87 for the total score
for children) (March et al. 1997, 1999). Reliability analyses
of the Dutch version revealed a Cronbach’s alpha of 0.93
(N=299, age 8–12) and a test-retest correlation of 0.81 for a
school based population (n=196, age 8–12).
The CDI is a 27-item scale suited for monitoring
changes in a child’s mood (Kovacs 1992). A Dutch version
of the CDI (Koot and van Widenfelt 2000) was used as a
continuous measure of depressed mood in the present study.
The CDI has good internal consistency (alphas ranging
from 0.71 (outpatient group) to 0.89) and acceptable test-
retest reliability (correlation of 0.75). The Dutch translation
showed good psychometric properties, the Cronbach’s
alpha was 0.82 for elementary school children (N=649,
age 8–12).
Parent-report Measures
The Child Behavior Checklist (CBCL) is a well-known and
researched 113 item scale that assesses child behavior
problems by parents (Achenbach and Rescorla 2001).
Verhulst et al. (1996) translated the CBCL into Dutch and
collected norm data on 1,422 clinically referred children.
This resulted in a standardized questionnaire with sound
psychometric properties for the scales ‘total behavior
problems’, ‘externalizing problems’ and ‘internalizing
problems’. Cronbachs alpha’s ranged for the above-
mentioned scales for the clinical norm group from 0.72 to
0.87. For the analyses in the present study the internalizing
problem scale (CBCL-Int) and the externalizing problem
scale (CBCL-Ext) of the 2002 translation was used
(Verhulst 2002). Norms for the Dutch 2002 version are
not available yet. Cronbachs alpha for the CBCL-Int,
CBCL-Ext and CBCL total, for fathers and mothers, ranged
for the present study from 0.88 to 0.96. For analytic
purposes a composite measure (“severity score”)w a s
calculated consisting of the mean Z-scores of mother and
father reported problem behavior (CBCL total score).
Treatment
Children were treated with the Dutch translation of the
FRIENDS program (Barrett and Turner 2000; Utens et al.
2001). Results from previous research indicate that
FRIENDS is an effective treatment for childhood anxiety
disorders (Shortt et al. 2001). The FRIENDS program is
based on the Coping Cat workbook (Kendall et al. 1990).
FRIENDS is a manualized treatment based on a theoretical
framework with three main target areas for change: physical
symptoms, cognitive processes and coping skills. Children
are taught coping techniques such as relaxation and
breathing exercises to learn to cope with physical symp-
toms of anxiety. Children are also taught to challenge
negative cognitions, irrational beliefs and negative self-talk
by changing them into helpful cognitions, realistic beliefs
and positive self-talk. Increased awareness of avoidant
behavior is stimulated, as well as the development of
problem solving and coping skills. In the second half of the
treatment, gradual exposure is introduced. Attempts to cope
constructively with anxiety are positively rewarded.
Children were assigned to either individual or group
CBT by sequential randomization. No significant differ-
ences in outcome (free of any anxiety disorders at post
treatment) between individual and group treatment were
found (χ² (1, 124)=0.55, p=0.46) (Liber et al. 2008a).
Treatment Integrity
Adherence was checked as part of the treatment integrity
measures. All therapy sessions were videotaped; a random
selection of 30% of the tapes of individual sessions and all
tapes of the group sessions were checked for adherence.
(For the training procedure of the coders; see Liber et al. in
press). Each session contained 6–12 therapeutic activities,
coders watched entire therapy sessions and then rated how
well the therapist met the aims of each activity on a four
point Likert-scale ranging from 1 (extremely well) to 4 (not
at all). Scores 1 and 2 were recoded into ‘met’ (1) and
scores 3 and 4 were recoded into ‘not met’ (0) in order to
calculate the percentage of adherence to the treatment
J Abnorm Child Psychol (2010) 38:683–694 687protocol. It should be noted that adherence to the treatment
protocol is an implementation check, and not an evaluation
of the competence of the therapists. Percentages of ‘met’
were calculated per available session, and subsequently
averaged over the available sessions per child. Results
indicated that therapists adhered satisfactorily to the
treatment protocol (94% of the child sessions and 85% of
the parent sessions were provided as intended). Adherence
rates for child sessions were higher than adherence rates for
parent sessions (t(117)=6.83, p<0.01). The total and non-
anxiety comorbidity groups did not differ with regard to
adherence to the treatment protocol (total comorbidity child
sessions; t(117)=0.56, p = ns, total comorbidity parent
sessions; t(114)=1.08, p = ns, non-anxiety comorbidity
child sessions; t(117)=1.11, p = ns; non-anxiety comorbid-
ity parent sessions; t(114)=1.60, p = ns). Twenty-three
therapists conducted the therapy sessions; six were doctoral
students and 17 were licensed psychologists. Therapists at
each institute met regularly to discuss the treatment and
were supervised by two experienced licensed cognitive
behavioral therapists. Every three to four months the




Regression analyses with hierarchical/ blockwise entry
were performed to investigate whether comorbidity has an
impact on treatment outcome above and beyond symptom
severity. Regression methods are regarded as robust
methods for use with clinical trials (Vickers 2005).
Prediction models with recovery as outcome measure are
conducted using logistic regression, prediction models with
change as outcome measure are performed using multiple
regression. As there is empirical evidence that severity does
(Doss and Weisz 2006; Manassis et al. 2004), and
comorbidity does not predict child anxiety CBT outcome
(Kendall et al. 2001; Rapee 2003), severity is entered in the
first block, and total and non-anxiety comorbidity are
entered in the second block. Thereby investigating whether
comorbidity has an impact on treatment outcome above and
beyond symptom severity. As total and non-anxiety
comorbidity are substantially related (Spearman’s r=0.42,
p<0.001), regression analyses were run twice, with total
comorbidity in the first model and non-anxiety comorbidity
in a separate second model.
Reliable Change and Treatment Recovery
In the present study Reliable Change and Treatment
Recovery are included as dependent variables. Change
was determined by Reliable Change scores (RC scores).
Reliable Change is calculated using a method that corrects
for error-based regression to the mean (RC score). RC
scores were computed for the CBCL-Int and Ext, the
MASC and CDI. RC scores are used because they represent
the most precise estimation of the true pre-post differences
and are a more conservative approach than using the
observed difference score (for a detailed description see
Liber et al. 2008b). Negative RC scores reflect a reliable
reduction in symptoms; improved RC score is defined by
an RC score below−1.65. In the present study, treatment
recovery is a dichotomy of ‘recovered’ versus ‘not/ partially
recovered’. Treatment Recovery on the continuous anxiety
measures (i.e., the MASC and the CBCL-Int) was
defined as an improved RC score and a post score
indicating ‘normal functioning’ as determined by the
CSINDIV score. The CSINDIV score was computed using
cutoff type c (see Hageman and Arrindell 1999). A
CSINDIV score <−1.65 is used to conclude that the
individual client has passed the cutoff for ‘normal’
functioning. Treatment Recovery on the CBCL-Int for
mothers and father were combined: if the CBCL-Int RC score
and CSINDIV score of one of the parents were both <−1.65,
the outcome was considered successful (coded as 1) unless
the CBCL-Int RC score of the other parent indicated
deterioration, i.e. a RC score >1.65 (‘deteriorated’)( c o d e d
as 0). The CS of the CBCL Int scores for mothers and fathers
showed a correlation of 0.67 (p<0.001).
Treatment Recovery is also determined by post treat-
ment diagnostic status (presence (1) or absence (0) of any
anxiety disorder as assessed with the ADIS C/P).
Treatment recovery based on diagnostic status indicates
that children were free of any anxiety disorder at post-
treatment according to the overall ADIS-C/P severity
rating; child, parent and clinicians severity ratings were
below threshold (below 4).
Treatment Recovery was determined for anxiety meas-
ures only, given the focus of the treatment. Reliable Change
was calculated for anxiety measures as well as measures on
externalizing and depressive symptoms to explore potential
differential effects of the predictors. Treatment Recovery
and Reliable Change are both presented as they function as
complementary indices of treatment outcome; Treatment




To explore whether comorbidity and severity were related,
biserial correlation coefficients were calculated. Biserial
688 J Abnorm Child Psychol (2010) 38:683–694correlation coefficients revealed small to moderate correla-
tion coefficients between total comorbidity and severity,
and between non-anxiety comorbidity and severity (rb=
0.20, rb=0.37 respectively).
Comorbidity and Severity as Predictors for Recovery
on Anxiety Measures
Logistic regression analyses showed that recovery on the
MASC, CBCL-Int and ADIS-C/P was significantly pre-
dicted by severity (see Table 2). The Odds Ratios (OR)
indicate that recovery was less likely for children with
higher levels of pretreatment overall severity. In the second
block of the logistic regressions comorbidity status was
entered: total comorbidity (step 2A) or non-anxiety comor-
bidity (step 2B). Total and non-anxiety comorbidity added
significantly to the prediction of recovery on the ADIS-C/P.
Children with non-anxiety and total comorbidity were less
likely to have recovered. Adding non-anxiety comorbidity
significantly increased the prediction of recovery on the
MASC, with a growth of 6% of Nagelkerke’s R
2; a measure
of pseudo-variance that ranges from 0 to 1. However, the
OR of severity was no longer significant and the OR of
non-anxiety comorbidity only approached significance (p<
0.10), indicating that severity and non-anxiety comorbidity
are overlapping predictors of recovery on the MASC.
Comorbidity and Severity as Predictors for Reliable Change
on Anxiety Measures
Multiple regression analyses with severity (in the first step)
and comorbidity status (second steps) as predictor variables
did not show any significant association between the
predictors and Reliable Change on the MASC. As can be
seen in Table 3, severity was a significant predictor of
Reliable Change in CBCL-Internalizing symptoms. Enter-
ing non-anxiety comorbidity (in Step 2B) resulted in a
better prediction with a higher absolute beta value of
severity. The higher absolute value indicates a suppressor
situation (see e.g. Paulhus et al. 2004). In addition to testing
the significance of R
2Δ, we used the Sobel test to evaluate
the significance of the difference between the beta values of
severity (see MacKinnon et al. 2000). Identical with the
result of testing R
2Δ, we found that the negative effect of
severity was significantly more negative after non-anxiety
comorbidity was included in the equation: z=2.06, p<0.05.
As the correlation of non-anxiety comorbidity with Reliable
Change in CBCL-Internalizing is near zero (r=0.06), this
Variables B OR (Exp(B)) 95% CI of OR χ
2 Step Nagk R
2 Model
Analysis for MASC
Step 1 6.12* 0.07
Severity* −0.53 0.59 0.38–0.91
Step 2A 0.27 0.07
Severity* −0.51 0.60 0.39–0.94
Total Comorbidity −0.21 0.81 0.38–1.77
Step 2B 4.12* 0.11
Severity −0.38 0.69 0.43–1.09
NAC
+ −1.27 0.28 0.07–1.07
Analysis for CBCL-Int
#
Step 1 9.55** 0.14
Severity** −1.04 0.35 0.17–0.75
Step 2A 2.99
+ 0.18
Severity** −1.18 0.31 0.14–0.68
Total Comorbidity 1.03 2.79 0.83–9.36
Analysis for ADIS-C/P
Step 1 22.06*** 0.22
Severity*** −1.07 0.34 0.21–0.57
Step 2A 6.92* 0.29
Severity*** −1.00 0.37 0.22–0.61
Total Comorbidity* −1.08 0.34 0.15–0.76
Step 2B 5.37* 0.27
Severity*** −0.88 0.41 0.25–0.70
NAC* −1.63 0.20 0.04–0.95
Table 2 Logistic Regression
Predicting Recovery on MASC,
CBCL-Int and ADIS-C/P
MASC Multidimensional Anxiety
Scale for Children; CBCL-Int
Child Behavior Checklist, Inter-
nalizing Scale; ADIS-C/PAnxiety
Disorders Interview Schedule,
Child & Parent; NAC non-
anxiety comorbidity; MASC,
CBCL and ADIS-C/P recovery =
1, no recovery = 0; Non-anxiety
comorbidity and total comorbid-
i t y ;p r e s e n t=1 ,a b s e n t=0 ;B =
Logistic Coefficient; OR = Odds
Ratio; Nagk R
2 =N a g e l k e r k e
R
2; Zero to five outliers were
removed from a model;
# Step 2B not realized because of
a low expected number of recov-
ered cases with non-anxiety
comorbidity (as only 16% of all
cases was recovered on CBCL-Int,
the expected number recovered
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Classical suppression implies mutual suppression (Paulhus
et al. 2004), i.e. the stronger prediction found by combining
both predictors indicates that non-anxiety comorbidity
removes irrelevant variance from severity and vice versa.
In a configuration with a classical suppressor variable both
predictors suppress some of each others irrelevant variance.
The removal of this ‘contamination’ may result in more
‘pure’ measures. As indicated by the negative beta value of
severity and the positive beta value of non-anxiety
comorbidity, children with more parent reported overall
severity are more likely to show greater pre to post-
treatment changes, but to a lesser extent if they suffer from
a comorbid disorder other than anxiety.
Severity and Comorbidity as Predictors for Reliable Change
in Depressive and Externalizing Symptoms
Multiple regression analyses were used to predict reliable
change in depressive and externalizing symptoms. Again,
severity was entered in the first step and total comorbidity
and non-anxiety comorbidity respectively in the second
step. Severity significantly predicted Reliable Change in
self-reported depressive symptoms (CDI) and in parent
reported externalizing problems (CBCL-Ext, see Table 3).
The negative beta-values for the severity scores in the
prediction of reliable change on the CDI and CBCL-Ext
scales indicate more improvement (e.g., negative RC
values) for children with higher levels of severity.
The addition of ‘non-anxiety comorbidity’ significantly
increased the prediction of reliable change on the CDI and
the CBCL-Ext. Interestingly, severity was no longer a
significant predictor of the CDI after entering ‘non-anxiety
comorbidity’ (step 2B), thereby indicating that ‘non-anxiety
comorbidity’ explained all of the variance in CDI improve-
ment associated with severity.
The higher beta of severity in predicting improvement
in CBCL-Ext at step 2B, indicates that ‘non-anxiety
comorbidity’ could be a suppressor variable. This was
affirmed by the significant value of R
2Δ a n db yt h er e s u l t
of the Sobel test: z=2.55, p<0.05, indicating that the
negative effect of severity was significantly more negative
after non-anxiety comorbidity was included in the equa-
tion. Non-anxiety comorbidity is again a classical sup-
pressor as near-zero correlation (r=0.10) was found
between this predictor and the dependent variable. So
again, a stronger predictive value of both predictors was
found, indicating the removal of irrelevant variance from
overall severity by non-anxiety comorbidity and vice
versa. Change in pre- to post treatment symptoms is more
likely for children with a higher level of overall severity,
but to a lesser extent if they suffer from a comorbid
disorder other than anxiety. Treatment format did not
improve the models
1.





Step 1 0.15*** 0.15***
Severity*** −0.56 0.13 −0.39
Step 2B 0.04* 0.19***
Severity*** −0.70 0.14 −0.48
NAC* 0.76 0.33 0.22
Analysis for CDI
#
Step 1 0.07** 0.07**
Severity** −0.20 0.07 −0.27
Step 2B 0.06** 0.13***
Severity −0.12 0.08 −0.15
NAC** −0.53 0.19 −0.27
Analysis for CBCL-Ext#
Step 1 0.16*** 0.16***
Severity*** −0.56 0.12 −0.40
Step 2B 0.06** 0.22***
Severity*** −0.70 0.12 −0.50
NAC** 0.97 0.31 0.28
Table 3 Multiple Regression
Predicting Reliable Change on
CDI, CBCL-Int and CBCL-Ext
NAC non-anxiety comorbidity;
CDI Children’s Depression In-
ventory; CBCL Child Behavior
Checklist, Int Internalizing Scale
and Ext Externalizing Scale;
Non-anxiety comorbidity and
total comorbidity: present = 1,
absent = 0. Three to five outliers
were removed from a model;
+p
<0.10; *: p<0.05; **: p<0.01;
***: p<0.001;
# Step 2A not
computed because no significant
association was found with total
comorbidity.
1 Children were randomly assigned to individual CBT or group CBT.
Though previous analyses showed no differences in outcome between
these formats (Liber et al. 2008a), interaction effects for comorbidity x
treatment format were not yet examined. Therefore all analyses were
rerun including interaction effects of our initial predictors with
treatment format. None of the models improved by including
treatment format.
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In the present study, children with a higher level of pre-
treatment symptom severity were less likely to have
recovered at post-treatment. Further, children with any
comorbid disorder (total comorbidity) at pre-treatment were
less likely to be free of a DSM-IV anxiety disorder at post-
treatment. Pre-treatment non-anxiety comorbidity added to
the prediction of recovery when recovery was assessed with
child reported anxiety symptoms. Thus both increased
symptom severity and having a nonanxiety comorbid
disorder at pretreatment predicts recovery when outcome
is assessed using self-reports of anxiety. Total comorbidity
did not add to the prediction of recovery using child-
reported anxiety nor parent-reported internalizing symp-
toms over and above the contribution of symptom severity.
Children with a higher level of pretreatment severity
need greater decreases in symptoms to reach a sub-
threshold level of symptoms, therefore we also examined
pre to posttreatment Reliable Change. Severity and
comorbidity did not contribute to the prediction of
Reliable Change when based on self-reported anxiety
symptoms. Though children with a higher level of
overall severity and non-anxiety comorbidity are less
likely to show clinically significant recovery in terms of
clinician rated DSM-IV diagnoses, they are equally likely
to gain from the treatment when children are asked to
report on anxiety symptoms. Conversely, severity pre-
dicted greater Reliable Change in parent reported
internalizing and externalizing symptoms, and child
reported depressive symptoms. Having a non-anxiety
comorbidity added to this prediction when assessing
parent-reported internalizing, externalizing and child-
reported depressive symptoms, but in different ways.
Non-anxiety comorbidity was the dominant predictor for
Reliable Change in self-reported depressive symptoms,
incorporating the predictive value of severity. In the
predictions of Reliable Change of parent-reported inter-
nalizing and externalizing child symptoms, non-anxiety
comorbidity could be classified as a classical suppressor
variable. Severity is strongly associated with more
improvement when irrelevant variance in common with
non-anxiety comorbidity is removed, therefore researchers
should consider removing the irrelevant variance of parent-
reported pre-treatment overall severity when considering
relations between non-anxious comorbidity and parent
reported change in internalizing and externalizing problems.
The results indicate the importance of assessing recovery
both in terms of treatment recovery and Reliable Change
scores, as well as the investigation of treatment outcome from
a multi-informant perspective. Similar to Doss and Weisz
(2006), we found higher initial severity to be predictive of
both greater treatment gains (reliable change) and higher
levels of remaining symptoms. In line with previous studies
we found only a modest predictive value of total comorbidity
on treatment outcome (i.e., Flannery-Schroeder et al. 2004;
Kendall et al. 2001; Rapee 2003). However, the presence of
a non-anxiety comorbid disorder at pretreatment added
significantly to predictions of treatment recovery based on
a clinical interview and child-reported anxiety symptoms and
for Reliable Change on depressive, internalizing and
externalizing symptoms.
The current findings may help identify those children
that need additional treatment after a basic CBT program.
Children with a higher level of overall severity might
benefit from a stepped care approach (Bower and Gilbody
2005) in which additional treatment is necessary to reach
the subthreshold level of symptoms. A generic program
might be sufficient, as children with higher overall severity
tend to show greater changes with such programs. If they
also suffer from a non-anxiety comorbid disorder then they
might benefit from a combined, modular or prescriptive
treatment (Chorpita et al. 2004) in which non-anxiety
problems are also targeted. Future studies on stepped care,
modular or prescriptive treatment could evaluate strategies
targeting anxiety as well as strategies targeting comorbid
problems for these children.
There might be a positive spin-off of this generic
anxiety-focused CBT treatment leading to a decrease in
co-occurring depressive symptoms and externalizing symp-
toms. A greater change in depressive symptoms was
associated with the presence of having another disorder at
pretreatment. Similarly, another treatment outcome study
also reported greater decreases in depressive scores in
depressed adolescents with pretreatment comorbid anxiety
disorders. These adolescents had more room for improve-
ment as they reported significantly higher depression scores
at intake (Rohde et al. 2001). We did find an effect of non-
anxiety comorbid disorders on externalizing symptoms;
non-anxiety comorbidity did have a negative impact on
change in externalizing symptoms in anxious children when
suppressor effects were taken into account. A recent study
evaluated the effectiveness of an intervention for anxiety
disorders and comorbid aggression (Levy et al. 2007).
Children were treated with either a CBT program for
anxiety only or a CBT intervention targeting both anxiety
and comorbid aggression. Both interventions led to signif-
icant reductions in externalizing and internalizing parent
reported problem behavior, and the combined treatment
program did not show a higher effectiveness. Unfortunately,
the study did not assess severity separately. Similar to Levy
et al. we found no associations between the presence of
non-anxiety comorbidity and reductions of internalizing
and externalizing parent-reported problems with anxiety-
focused CBT. However, we also investigated the combined
prediction of comorbidity and overall severity and found
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anxiety comorbidity has a negative impact on reduction of
internalizing and externalizing problems. In addition, there
is sufficient evidence from meta-analyses that certain
treatments are effective for certain types of problems, e.g.
parent training for externalizing problems or exposure for
phobia (Chambless and Ollendick 2001). Investigation of
the combined impact of comorbidity and overall severity on
the potency of treatments for various primary diagnoses
may inform us how to enhance treatments for primary
disorders as well as comorbid conditions.
Important assets of the present study are the multi-
informant perspective on treatment outcome, assessment of
changes not only in anxiety but also in anxiety-related and
comorbid symptoms, use of a clinically meaningful method
to define treatment recovery and computation of reliable pre
to post-treatment changes.
For the present study, children with comorbid con-
ditions other than anxiety were treated as one group,
whereas the investigation of children with comorbid
externalizing disorders versus comorbid affective disor-
ders could also prove fruitful. Comorbidity of anxiety
with an affective disorder or comorbidity with an
externalizing disorder may be more common in commu-
nity samples and therefore of clinical value to investi-
gate. As only 17% of the children in the current study
showed a comorbid disorder other than anxiety, the
power did not permit a further splitting of this group.
Moreover, the sample of children with a comorbid
disorder other than anxiety (n=22) included 4 children
with both a mood disorder and an externalizing disorder.
Though the sample size in the present study is quite large,
it was designed to investigate main effects and not
designed for interaction effects. An adequate test of an
interaction requires an even larger sample size than for
detecting a simple main effect (Shoham-Salomon and
Hannah 1991). These considerations point at the need for
an adequately powered trial testing the mechanisms
through which comorbidity might interact with treatment.
A further limitation of the present study is that we only
assessed at post-treatment the presence or absence of
anxiety disorders, and not the absence or presence of
affective or externalizing disorders. Assessing comorbid
diagnoses could give further insight into the impact of
comorbidity on the treatment process. Kendall et al. (2001)
found that children with the continued presence of
comorbidity were less likely to recover from their primary
pretreatment diagnosis. Additionally, five children were on
a consistent dose of medication for ADHD.It is not known
whether the negative impact of comorbid conditions on
anxiety and externalizing symptoms or the positive impact
on depressive symptoms would have been stronger if
children had not been on medication for ADHD. However,
it was deemed unethical to withhold medication from
children with ADHD for research purposes.
It can be argued that severity should not be investigated
using a sole additive construct with symptoms of one sort
counting the same as that of another, i.e., itching and
suicidal ideation. However, differentiating between symp-
toms and prioritizing some above others would be difficult
to calculate and not be representative of the severity
construct. Future studies could incorporate an impairment
measure such as the DSM global functioning scale in
addition to parent reported overall severity.
In sum, severity predicted less favorable child, parent
and clinician reported outcomes but greater pre- to post-
treatment changes in parent-reported internalizing symp-
toms. Non-anxiety comorbidity added significantly to these
predictions in a number of ways: as a separate predictor (in
predicting recovery on ADIS), as predictor overlapping
with severity (in predicting recovery on the MASC), as
suppressor variable (in predicting Reliable Change on
internalizing and externalizing CBCL-scales) and as dom-
inant predictor (in predicting Reliable Change on the CDI).
Future studies but also clinicians should take into account
the potential impact of symptom severity on outcome. As
severity and comorbid disorders only explain part of the
variance in outcome a further understanding of valid
predictors is essential to understand who does not benefit
sufficiently from CBT for CAD. Replication of the current
findings with severity and non-anxiety comorbidity as
separate constructs are necessary to further our understand-
ing on how symptoms and comorbid patterns of problem
behavior change with anxiety focused CBT.
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